Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more
Kancera AB (publ) (KAN) - Net Assets
Latest net assets as of June 2025: Skr43.12 Million SEK
Based on the latest financial reports, Kancera AB (publ) (KAN) has net assets worth Skr43.12 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr46.70 Million) and total liabilities (Skr3.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr43.12 Million |
| % of Total Assets | 92.34% |
| Annual Growth Rate | 13.13% |
| 5-Year Change | -13.81% |
| 10-Year Change | 184.15% |
| Growth Volatility | 115.86 |
Kancera AB (publ) - Net Assets Trend (2010–2024)
This chart illustrates how Kancera AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kancera AB (publ) (2010–2024)
The table below shows the annual net assets of Kancera AB (publ) from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr62.30 Million | +30.70% |
| 2023-12-31 | Skr47.66 Million | -55.42% |
| 2022-12-31 | Skr106.91 Million | -12.75% |
| 2021-12-31 | Skr122.54 Million | +69.52% |
| 2020-12-31 | Skr72.28 Million | +314.97% |
| 2019-12-31 | Skr17.42 Million | -47.78% |
| 2018-12-31 | Skr33.36 Million | -13.83% |
| 2017-12-31 | Skr38.71 Million | -34.97% |
| 2016-12-31 | Skr59.52 Million | +171.49% |
| 2015-12-31 | Skr21.93 Million | -19.66% |
| 2014-12-31 | Skr27.29 Million | +43.96% |
| 2013-12-31 | Skr18.96 Million | +244.72% |
| 2012-12-31 | Skr5.50 Million | -78.77% |
| 2011-12-31 | Skr25.90 Million | +134.01% |
| 2010-12-31 | Skr11.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kancera AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4456600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.78 Million | 18.91% |
| Other Components | Skr95.09 Million | 152.63% |
| Total Equity | Skr62.30 Million | 100.00% |
Kancera AB (publ) Competitors by Market Cap
The table below lists competitors of Kancera AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Forbidden Foods Ltd
AU:FFF
|
$1.49 Million |
|
Oscar Properties Holding AB
ST:OP
|
$1.49 Million |
|
Lord Resources Ltd
AU:LRD
|
$1.49 Million |
|
MetaVia Inc.
NASDAQ:MTVA
|
$1.49 Million |
|
Universal Biosensors Inc
AU:UBI
|
$1.49 Million |
|
Asiabasemetals Inc
V:ABZ
|
$1.49 Million |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
$1.49 Million |
|
Alakasa Industrindo Tbk
JK:ALKA
|
$1.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kancera AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 47,665,000 to 62,300,000, a change of 14,635,000 (30.7%).
- Net loss of 44,566,000 reduced equity.
- Share repurchases of 59,201,000 reduced equity.
- New share issuances of 59,201,000 increased equity.
- Other factors increased equity by 59,201,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-44.57 Million | -71.53% |
| Share Repurchases | Skr59.20 Million | -95.03% |
| Share Issuances | Skr59.20 Million | +95.03% |
| Other Changes | Skr59.20 Million | +95.03% |
| Total Change | Skr- | 30.70% |
Book Value vs Market Value Analysis
This analysis compares Kancera AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr4.16 | Skr0.15 | x |
| 2011-12-31 | Skr8.89 | Skr0.15 | x |
| 2012-12-31 | Skr1.52 | Skr0.15 | x |
| 2013-12-31 | Skr3.69 | Skr0.15 | x |
| 2014-12-31 | Skr2.10 | Skr0.15 | x |
| 2015-12-31 | Skr1.50 | Skr0.15 | x |
| 2016-12-31 | Skr3.68 | Skr0.15 | x |
| 2017-12-31 | Skr2.13 | Skr0.15 | x |
| 2018-12-31 | Skr1.53 | Skr0.15 | x |
| 2019-12-31 | Skr0.68 | Skr0.15 | x |
| 2020-12-31 | Skr1.64 | Skr0.15 | x |
| 2021-12-31 | Skr1.83 | Skr0.15 | x |
| 2022-12-31 | Skr1.80 | Skr0.15 | x |
| 2023-12-31 | Skr0.60 | Skr0.15 | x |
| 2024-12-31 | Skr0.54 | Skr0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kancera AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -318328.57%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-71.53%) is above the historical average (-120.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -64.57% | 0.00% | 0.00x | 1.27x | Skr-8.25 Million |
| 2011 | -71.07% | -260.43% | 0.18x | 1.53x | Skr-21.00 Million |
| 2012 | -608.98% | -872.31% | 0.21x | 3.40x | Skr-34.04 Million |
| 2013 | -39.13% | -409.16% | 0.07x | 1.35x | Skr-9.31 Million |
| 2014 | -58.55% | -3399.79% | 0.01x | 1.33x | Skr-18.71 Million |
| 2015 | -89.45% | -6954.61% | 0.01x | 1.25x | Skr-21.80 Million |
| 2016 | -37.48% | -7242.86% | 0.00x | 1.23x | Skr-28.26 Million |
| 2017 | -145.17% | -49732.74% | 0.00x | 1.32x | Skr-60.07 Million |
| 2018 | -137.71% | -12831.01% | 0.01x | 1.37x | Skr-49.27 Million |
| 2019 | -207.22% | -1122.36% | 0.07x | 2.55x | Skr-37.84 Million |
| 2020 | -56.03% | -45000.00% | 0.00x | 1.15x | Skr-47.73 Million |
| 2021 | -37.28% | -2681.10% | 0.01x | 1.09x | Skr-57.94 Million |
| 2022 | -49.09% | -6969.99% | 0.01x | 1.13x | Skr-63.18 Million |
| 2023 | -136.14% | -6269.47% | 0.02x | 1.38x | Skr-69.66 Million |
| 2024 | -71.53% | -318328.57% | 0.00x | 1.07x | Skr-50.80 Million |
Industry Comparison
This section compares Kancera AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kancera AB (publ) (KAN) | Skr43.12 Million | -64.57% | 0.08x | $1.49 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |